FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W2297816245> ?p ?o ?g. }

• W2297816245 endingPage "2204" @default.
• W2297816245 startingPage "2195" @default.
• W2297816245 abstract "Allogeneic bone marrow transplantation (BMT) is the only effective treatment for hematologic malignancies resistant to conventional chemotherapy. Until recently, no cure existed for patients who relapsed post-BMT. We present our long-term observations on remission induction, after relapse post-BMT, by allogeneic cell therapy (allo-CT) and the feasibility of remission induction in allo-CT-resistant patients by activation of antileukemia effector cells with recombinant human interleukin-2 (rhIL-2) in vitro and in vivo. The longest observation of successful allo-CT (event-free survival, greater than 8 years) was made in a patient with resistant pre-B lymphoblastic leukemia who received infusions with graded increments of donor (female) peripheral blood lymphocytes (PBL) as soon as bulky hematologic and extramedullary relapse was noticed early post-BMT. The patient is currently without evidence of residual host (male) cells as determined by polymerase chain reaction (PCR). Of 17 patients with acute and chronic leukemia in relapse after BMT, 10 were reinduced into complete remission. Four patients with cytogenetic relapse responded to allo-CT alone, while five of six patients with overt hematologic relapse responded only after additional activation of donor with rhIL-2. Allo-CT can, therefore, successfully reverse chemoradiotherapy-resistant relapse of both acute and chronic leukemia. Moreover, in patients resistant to donor lymphocyte infusion, remission can be accomplished by additionally activating donor PBL in vitro and/or in vivo with rhIL-2. Based on our observations, after BMT, allo-CT should be considered the treatment of choice for patients with hematologic malignancies resistant to conventional anticancer modalities. Allogeneic activated cell therapy (allo ACT) should be considered for patients with tumor cells resistant to allo-CT. Although allo-CT, followed if indicated by allo-ACT, can be effective for patients with overt hematologic relapse, reversal of persistent minimal residual disease or documented molecular/cytogenetic relapse early after BMT may also be considered as a possible indication for allo-CT." @default.
• W2297816245 created "2016-06-24" @default.
• W2297816245 creator A5015397357 @default.
• W2297816245 creator A5029328757 @default.
• W2297816245 creator A5030282008 @default.
• W2297816245 creator A5045116114 @default.
• W2297816245 creator A5058925624 @default.
• W2297816245 creator A5059915616 @default.
• W2297816245 creator A5074117972 @default.
• W2297816245 creator A5082078271 @default.
• W2297816245 date "1996-03-15" @default.
• W2297816245 modified "2023-10-10" @default.
• W2297816245 title "Allogeneic cell therapy with donor peripheral blood cells and recombinant human interleukin-2 to treat leukemia relapse after allogeneic bone marrow transplantation" @default.
• W2297816245 cites W1274344746 @default.
• W2297816245 cites W1489421828 @default.
• W2297816245 cites W1489678151 @default.
• W2297816245 cites W1514304836 @default.
• W2297816245 cites W1547437950 @default.
• W2297816245 cites W1575533059 @default.
• W2297816245 cites W1592418294 @default.
• W2297816245 cites W1766242208 @default.
• W2297816245 cites W1894913781 @default.
• W2297816245 cites W1934171667 @default.
• W2297816245 cites W1965725959 @default.
• W2297816245 cites W1977635228 @default.
• W2297816245 cites W1981715129 @default.
• W2297816245 cites W1992401639 @default.
• W2297816245 cites W2001499325 @default.
• W2297816245 cites W2007342600 @default.
• W2297816245 cites W2019215987 @default.
• W2297816245 cites W2022584463 @default.
• W2297816245 cites W2044832723 @default.
• W2297816245 cites W2067480394 @default.
• W2297816245 cites W2076636340 @default.
• W2297816245 cites W2078123170 @default.
• W2297816245 cites W2087653021 @default.
• W2297816245 cites W2108782166 @default.
• W2297816245 cites W2117581174 @default.
• W2297816245 cites W216764306 @default.
• W2297816245 cites W2204379292 @default.
• W2297816245 cites W2226146977 @default.
• W2297816245 cites W2309081305 @default.
• W2297816245 cites W2312539315 @default.
• W2297816245 cites W2318523525 @default.
• W2297816245 cites W2325605534 @default.
• W2297816245 cites W2340547456 @default.
• W2297816245 cites W2396193493 @default.
• W2297816245 cites W2400663726 @default.
• W2297816245 cites W2409157990 @default.
• W2297816245 cites W2411512664 @default.
• W2297816245 cites W2411955627 @default.
• W2297816245 cites W2413545310 @default.
• W2297816245 cites W2416148102 @default.
• W2297816245 cites W2416200206 @default.
• W2297816245 cites W2416259506 @default.
• W2297816245 cites W2425734506 @default.
• W2297816245 cites W2439745428 @default.
• W2297816245 cites W2465450180 @default.
• W2297816245 cites W2468646484 @default.
• W2297816245 cites W309638826 @default.
• W2297816245 cites W3112391182 @default.
• W2297816245 cites W44995847 @default.
• W2297816245 cites W79382124 @default.
• W2297816245 cites W91965583 @default.
• W2297816245 cites W2416145952 @default.
• W2297816245 doi "https://doi.org/10.1182/blood.v87.6.2195.bloodjournal8762195" @default.
• W2297816245 hasPubMedId "https://pubmed.ncbi.nlm.nih.gov/8630379" @default.
• W2297816245 hasPublicationYear "1996" @default.
• W2297816245 type Work @default.
• W2297816245 sameAs 2297816245 @default.
• W2297816245 citedByCount "419" @default.
• W2297816245 countsByYear W22978162452012 @default.
• W2297816245 countsByYear W22978162452013 @default.
• W2297816245 countsByYear W22978162452014 @default.
• W2297816245 countsByYear W22978162452015 @default.
• W2297816245 countsByYear W22978162452016 @default.
• W2297816245 countsByYear W22978162452017 @default.
• W2297816245 countsByYear W22978162452018 @default.
• W2297816245 countsByYear W22978162452019 @default.
• W2297816245 countsByYear W22978162452020 @default.
• W2297816245 countsByYear W22978162452021 @default.
• W2297816245 countsByYear W22978162452022 @default.
• W2297816245 countsByYear W22978162452023 @default.
• W2297816245 crossrefType "journal-article" @default.
• W2297816245 hasAuthorship W2297816245A5015397357 @default.
• W2297816245 hasAuthorship W2297816245A5029328757 @default.
• W2297816245 hasAuthorship W2297816245A5030282008 @default.
• W2297816245 hasAuthorship W2297816245A5045116114 @default.
• W2297816245 hasAuthorship W2297816245A5058925624 @default.
• W2297816245 hasAuthorship W2297816245A5059915616 @default.
• W2297816245 hasAuthorship W2297816245A5074117972 @default.
• W2297816245 hasAuthorship W2297816245A5082078271 @default.
• W2297816245 hasBestOaLocation W22978162451 @default.
• W2297816245 hasConcept C126322002 @default.
• W2297816245 hasConcept C143998085 @default.
• W2297816245 hasConcept C203014093 @default.
• W2297816245 hasConcept C2776611710 @default.
• W2297816245 hasConcept C2776694085 @default.

• next